MaxCyte Inc (NASDAQ:MXCT) is set to release its Q2 2025 earnings on August 6, 2025. The consensus estimate for Q2 2025 revenue is $9.57 million, and the earnings are expected to come in at -$0.10 per ...
MaxCyte, Inc. has announced the acquisition of SeQure Dx, a company specializing in assessing on-target and off-target gene editing for cell and gene therapies. This strategic move enhances MaxCyte's ...
MaxCyte, Inc. has announced preliminary financial results for the fourth quarter and full year of 2024, projecting core revenue between $8.3 million and $8.5 million for the fourth quarter, up from $7 ...
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor ...
MaxCyte: Building the Future of Cell and Gene Therapy Innovation MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue ...
ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (MXCT), (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing ...
MaxCyte's fourth quarter and full year results are preliminary, unaudited and subject to change in connection with the completion of MaxCyte's quarterly and year-end closing processes and review ...
FLORHAM PARK, N.J. and GAITHERSBURG, Md., May 25, 2021 /PRNewswire/ — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the ...
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results